Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Core Viewpoint - Regeneron Pharmaceuticals has launched a matching donation program to support Good Days' Retinal Vascular and Neovascular Disease Fund, committing to match donations up to $200 million for the remainder of 2025, aimed at improving patient access to essential medications for retinal diseases [1][2][3]. Group 1: Donation Program Details - The matching program will double donations made to Good Days, enhancing support for U.S. patients who meet specific criteria for copay assistance [2][4]. - Regeneron has a history of philanthropic efforts, having donated over $2.5 billion to independent charitable organizations in the past decade [4]. Group 2: Broader Commitment to Healthcare Access - This initiative is part of Regeneron's broader commitment to improving patient outcomes and healthcare access, which includes various support programs and collaborations with NGOs and public health agencies [3][4]. - The company emphasizes that donations are not intended to incentivize the use of any specific product and are provided without regard to the prescribed medication, as long as it is FDA-approved [2][4]. Group 3: Corporate Responsibility and Community Engagement - Regeneron aims to operate as a good corporate citizen, focusing on improving lives, fostering integrity, and building sustainable communities, and is recognized on the Dow Jones Sustainability World Index [6]. - The company encourages employee engagement in community service through various programs, with significant commitments in science education [6].